The technology will permit MDRNA to stabilize and provide drug-like properties to RISC and Dicer length small interfering RNAs (siRNAs) in a novel and proprietary manner. Terms of the agreement were not disclosed.
MDRNA has previously demonstrated that unlocked nucleic acid (UNA) has the potential to improve siRNA therapeutics by increasing stability and reducing sense- and antisense-mediated off-target effects while retaining potency.
Suzy Lena Wengel, co-founder and CEO of RiboTask, said: “While RiboTask is looking forward to commercializing the diagnostic and reagents applications of UNA, we are glad that this technology is in the hands of MDRNA whose scientific expertise and capabilities are necessary to bring UNA-siRNAi therapeutics to patients with significant unmet medical needs.”